Indaptus Therapeutics Q1 net loss narrows as expenses fall

Indaptus Therapeutics

15/05/2026 12:07

Overview

U.S. biotech firm's Q1 net loss narrowed as operating expenses declined

Company is reassessing development priorities after executive management transition

Cash and cash equivalents fell to $1.5 mln; company says more funding will be needed

Outlook

Company is reassessing development priorities and resource allocation following management changes

Indaptus continues to evaluate corporate initiatives and potential development opportunities

Company is assessing financing alternatives and strategic options to support its corporate strategy

Result Drivers

LOWER CLINICAL COSTS - Co said research and development expenses fell mainly due to decreased clinical costs related to its Phase 1 study

MANAGEMENT TRANSITION - Co cited recent executive management changes and ongoing operational and organizational adjustments

STRATEGIC REVIEW - Co is reassessing development priorities, operating initiatives and resource allocation as part of a broader review

Company press release: ID:nGNX7qJrZV

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.23


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)